Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): PMS-Diltiazem CD (02355752), PMS-Diltiazem CD (02355760), PMS-Diltiazem CD (02355779), PMS-Diltiazem CD (02355787), Teva-Diltazem (00862924), Teva-Diltazem (00862932). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
DILTIAZEM HCL
Form:
24 of 24 products shown
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (C08D) — coverage varies; not interchangeable
Verapamil (Isoptin): general benefit, Not a benefit
AA-Diltiaz · DIN 00771376 · 30mg · tablet
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Diltiaz · DIN 00771376
Manufacturer: A A Pharma Inc.; listing date 1996-10-01
Health Canada: Marketed since 2020-10-28 · brand AA-DILTIAZ · ATC C08DB01 DILTIAZEM · form Tablet · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 30 MG · company Aa pharma inc · schedule Prescription
AA-Diltiaz: Formulary list price $0.2168/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2168 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9172 · Verify on the e-Formulary ↗ (DIN 00771376)
Source record
DIN 00771376: AA-Diltiaz
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400054; group id 280; item number 0597; lccId None; manufacturer id AAP
Source form: Tab; strength: 30mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2168; ministry $0.2168
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00771376
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9172Interchangeable products
Cardizem · DIN 02097370 · not recorded
Shortage status: discontinued (2019-07-12, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00771376
Shortage record checked 2026-09-13T08:10:21.292534+00:00
AA-Diltiaz · DIN 00771384 · 60mg · tablet
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Diltiaz · DIN 00771384
Manufacturer: A A Pharma Inc.; listing date 1996-10-01
Health Canada: Marketed since 2020-06-22 · brand AA-DILTIAZ · ATC C08DB01 DILTIAZEM · form Tablet · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 60 MG · company Aa pharma inc · schedule Prescription
AA-Diltiaz: Formulary list price $0.3802/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3802 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9173 · Verify on the e-Formulary ↗ (DIN 00771384)
Source record
DIN 00771384: AA-Diltiaz
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400053; group id 280; item number 0598; lccId None; manufacturer id AAP
Source form: Tab; strength: 60mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3802; ministry $0.3802
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00771384
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9173Interchangeable products
Cardizem · DIN 02097389 · not recorded
Shortage status: resolved shortage (ended 2026-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00771384
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Tiazac XC: Formulary list price $1.0911/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.0911 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74195 · Verify on the e-Formulary ↗ (DIN 02256738)
Source record
DIN 02256738: Tiazac XC
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400161; group id 280; item number 0583; lccId None; manufacturer id BIO
Source form: ER Tab; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.0911; ministry $1.0911
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02256738
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74195
Shortage status: resolved shortage (ended 2025-09-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02256738
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Diltiaz CD · DIN 02230997 · 120mg · LA capsule
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Diltiaz CD · DIN 02230997
Manufacturer: Apotex Inc.; listing date 1997-08-28
Daily cost (source): $0.3634
Health Canada: Marketed since 2019-01-09 · brand APO-DILTIAZ CD · ATC C08DB01 DILTIAZEM · form Capsule (controlled-delivery) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Apotex inc · schedule Prescription
Apo-Diltiaz CD: Formulary list price $0.3634/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3634 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50278 · Verify on the e-Formulary ↗ (DIN 02230997)
Source record
DIN 02230997: Apo-Diltiaz CD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400133; group id 280; item number 0588; lccId None; manufacturer id APX
Source form: LA Cap; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3634; ministry $0.3634
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230997
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50278Interchangeable products
Cardizem CD · DIN 02097249 · $0.3634
Co Diltiazem CD · DIN 02370611 · $0.3634
Diltiazem CD · DIN 02400421 · $0.3634
Diltiazem CD · DIN 02445999 · $0.3634
Jamp Diltiazem CD · DIN 02528037 · $0.3634
M-Diltiazem CD · DIN 02546086 · $0.3634
Mar-Diltiazem CD · DIN 02484064 · $0.3634
Sandoz Diltiazem CD · DIN 02243338 · $0.3634
Teva-Diltazem CD · DIN 02242538 · $0.3634
Shortage status: active shortage (reported 2026-08-25, estimated to end 2027-01-29, last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02230997
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diltiazem CD · DIN 02400421 · 120mg · LA capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Diltiazem CD · DIN 02400421
Manufacturer: Sanis Health Inc.; listing date 2022-07-29
Daily cost (source): $0.3634
Health Canada: Marketed since 2022-04-20 · brand DILTIAZEM CD · ATC C08DB01 DILTIAZEM · form Capsule (controlled-delivery) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Sanis health inc · schedule Prescription
Diltiazem CD: Formulary list price $0.3634/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3634 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88523 · Verify on the e-Formulary ↗ (DIN 02400421)
Source record
DIN 02400421: Diltiazem CD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400133; group id 280; item number 0588; lccId None; manufacturer id SAI
Source form: LA Cap; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3634; ministry $0.3634
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02400421
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88523Interchangeable products
Apo-Diltiaz CD · DIN 02230997 · $0.3634
Cardizem CD · DIN 02097249 · $0.3634
Co Diltiazem CD · DIN 02370611 · $0.3634
Diltiazem CD · DIN 02445999 · $0.3634
Jamp Diltiazem CD · DIN 02528037 · $0.3634
M-Diltiazem CD · DIN 02546086 · $0.3634
Mar-Diltiazem CD · DIN 02484064 · $0.3634
Sandoz Diltiazem CD · DIN 02243338 · $0.3634
Teva-Diltazem CD · DIN 02242538 · $0.3634
Shortage status: anticipated shortage (last updated 2026-08-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02400421
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diltiazem CD · DIN 02445999 · 120mg · LA capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Diltiazem CD · DIN 02445999
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-07-31
Daily cost (source): $0.3634
Health Canada: Marketed since 2024-05-09 · brand DILTIAZEM CD · ATC C08DB01 DILTIAZEM · form Capsule (extended-release) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Diltiazem CD: Formulary list price $0.3634/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3634 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93126 · Verify on the e-Formulary ↗ (DIN 02445999)
Source record
DIN 02445999: Diltiazem CD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400133; group id 280; item number 0588; lccId None; manufacturer id SIV
Source form: LA Cap; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3634; ministry $0.3634
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02445999
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93126Interchangeable products
Apo-Diltiaz CD · DIN 02230997 · $0.3634
Cardizem CD · DIN 02097249 · $0.3634
Co Diltiazem CD · DIN 02370611 · $0.3634
Diltiazem CD · DIN 02400421 · $0.3634
Jamp Diltiazem CD · DIN 02528037 · $0.3634
M-Diltiazem CD · DIN 02546086 · $0.3634
Mar-Diltiazem CD · DIN 02484064 · $0.3634
Sandoz Diltiazem CD · DIN 02243338 · $0.3634
Teva-Diltazem CD · DIN 02242538 · $0.3634
Shortage status: anticipated shortage (last updated 2026-05-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02445999
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Diltiazem CD · DIN 02528037 · 120mg · LA capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Diltiazem CD · DIN 02528037
Manufacturer: Jamp Pharma Corporation; listing date 2023-01-31
Daily cost (source): $0.3634
Health Canada: Marketed since 2022-12-16 · brand JAMP DILTIAZEM CD · ATC C08DB01 DILTIAZEM · form Capsule (controlled-delivery) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Jamp pharma corporation · schedule Prescription
Jamp Diltiazem CD: Formulary list price $0.3634/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3634 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101730 · Verify on the e-Formulary ↗ (DIN 02528037)
Source record
DIN 02528037: Jamp Diltiazem CD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400133; group id 280; item number 0588; lccId None; manufacturer id JPC
Source form: LA Cap; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3634; ministry $0.3634
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02528037
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101730Interchangeable products
Apo-Diltiaz CD · DIN 02230997 · $0.3634
Cardizem CD · DIN 02097249 · $0.3634
Co Diltiazem CD · DIN 02370611 · $0.3634
Diltiazem CD · DIN 02400421 · $0.3634
Diltiazem CD · DIN 02445999 · $0.3634
M-Diltiazem CD · DIN 02546086 · $0.3634
Mar-Diltiazem CD · DIN 02484064 · $0.3634
Sandoz Diltiazem CD · DIN 02243338 · $0.3634
Teva-Diltazem CD · DIN 02242538 · $0.3634
Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-10-16, last updated 2026-07-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02528037
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Diltiazem CD · DIN 02546086 · 120mg · LA capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Diltiazem CD · DIN 02546086
Manufacturer: Mantra Pharma Inc.; listing date 2024-10-31
Daily cost (source): $0.3634
Health Canada: Marketed since 2024-08-26 · brand M-DILTIAZEM CD · ATC C08DB01 DILTIAZEM · form Capsule (controlled-delivery) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Mantra pharma inc · schedule Prescription
M-Diltiazem CD: Formulary list price $0.3634/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3634 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103480 · Verify on the e-Formulary ↗ (DIN 02546086)
Source record
DIN 02546086: M-Diltiazem CD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400133; group id 280; item number 0588; lccId None; manufacturer id MAT
Source form: LA Cap; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3634; ministry $0.3634
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02546086
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103480Interchangeable products
Apo-Diltiaz CD · DIN 02230997 · $0.3634
Cardizem CD · DIN 02097249 · $0.3634
Co Diltiazem CD · DIN 02370611 · $0.3634
Diltiazem CD · DIN 02400421 · $0.3634
Diltiazem CD · DIN 02445999 · $0.3634
Jamp Diltiazem CD · DIN 02528037 · $0.3634
Mar-Diltiazem CD · DIN 02484064 · $0.3634
Sandoz Diltiazem CD · DIN 02243338 · $0.3634
Teva-Diltazem CD · DIN 02242538 · $0.3634
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02546086
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Diltiazem CD · DIN 02484064 · 120mg · LA capsule
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Diltiazem CD · DIN 02484064
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2020-05-29
Daily cost (source): $0.3634
Health Canada: Marketed since 2020-03-30 · brand MAR-DILTIAZEM CD · ATC C08DB01 DILTIAZEM · form Capsule (controlled-delivery) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Diltiazem CD: Formulary list price $0.3634/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3634 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97439 · Verify on the e-Formulary ↗ (DIN 02484064)
Source record
DIN 02484064: Mar-Diltiazem CD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400133; group id 280; item number 0588; lccId None; manufacturer id MAR
Source form: LA Cap; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3634; ministry $0.3634
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02484064
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97439Interchangeable products
Apo-Diltiaz CD · DIN 02230997 · $0.3634
Cardizem CD · DIN 02097249 · $0.3634
Co Diltiazem CD · DIN 02370611 · $0.3634
Diltiazem CD · DIN 02400421 · $0.3634
Diltiazem CD · DIN 02445999 · $0.3634
Jamp Diltiazem CD · DIN 02528037 · $0.3634
M-Diltiazem CD · DIN 02546086 · $0.3634
Sandoz Diltiazem CD · DIN 02243338 · $0.3634
Teva-Diltazem CD · DIN 02242538 · $0.3634
Shortage status: resolved shortage (ended 2022-03-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02484064
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Diltazem CD · DIN 02242538 · 120mg · LA capsule
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Diltazem CD · DIN 02242538
Manufacturer: Teva Canada Limited; listing date 2001-06-07
Daily cost (source): $0.3634
Health Canada: Marketed since 2024-10-07 · brand TEVA-DILTIAZEM CD · ATC C08DB01 DILTIAZEM · form Capsule (controlled-delivery) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Teva canada limited · schedule Prescription
Teva-Diltazem CD: Formulary list price $0.3634/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3634 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66289 · Verify on the e-Formulary ↗ (DIN 02242538)
Source record
DIN 02242538: Teva-Diltazem CD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400133; group id 280; item number 0588; lccId None; manufacturer id TEV
Source form: LA Cap; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3634; ministry $0.3634
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242538
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66289Interchangeable products
Apo-Diltiaz CD · DIN 02230997 · $0.3634
Cardizem CD · DIN 02097249 · $0.3634
Co Diltiazem CD · DIN 02370611 · $0.3634
Diltiazem CD · DIN 02400421 · $0.3634
Diltiazem CD · DIN 02445999 · $0.3634
Jamp Diltiazem CD · DIN 02528037 · $0.3634
M-Diltiazem CD · DIN 02546086 · $0.3634
Mar-Diltiazem CD · DIN 02484064 · $0.3634
Sandoz Diltiazem CD · DIN 02243338 · $0.3634
Shortage status: active shortage (reported 2026-06-10, estimated to end 2026-11-10, last updated 2026-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242538
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diltiazem T · DIN 02516101 · 120mg · extended release capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Diltiazem T · DIN 02516101
Manufacturer: Sanis Health Inc.; listing date 2021-12-17
Daily cost (source): $0.2133
Health Canada: Marketed since 2021-10-15 · brand DILTIAZEM T · ATC C08DB01 DILTIAZEM · form Capsule (extended-release) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Sanis health inc · schedule Prescription
Diltiazem T: Formulary list price $0.2133/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2133 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100545 · Verify on the e-Formulary ↗ (DIN 02516101)
Source record
DIN 02516101: Diltiazem T
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400145; group id 280; item number 0592; lccId None; manufacturer id SAI
Source form: SR Cap; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2133; ministry $0.2133
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02516101
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100545Interchangeable products
Jamp Diltiazem T · DIN 02495376 · $0.2133
M-Diltiazem T · DIN 02546434 · $0.2133
Mar-Diltiazem T · DIN 02465353 · $0.2133
Sandoz Diltiazem T · DIN 02245918 · $0.2133
Teva-Diltiazem HCL ER · DIN 02271605 · $0.2133
Teva-Diltiazem T · DIN 02370441 · $0.2133
Tiazac · DIN 02231150 · $0.2133
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02516101
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Diltiazem T · DIN 02495376 · 120mg · extended release capsule
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Diltiazem T · DIN 02495376
Manufacturer: Jamp Pharma Corporation; listing date 2020-11-30
Daily cost (source): $0.2133
Health Canada: Marketed since 2021-07-03 · brand JAMP DILTIAZEM T · ATC C08DB01 DILTIAZEM · form Capsule (extended-release) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Jamp pharma corporation · schedule Prescription
Jamp Diltiazem T: Formulary list price $0.2133/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2133 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98529 · Verify on the e-Formulary ↗ (DIN 02495376)
Source record
DIN 02495376: Jamp Diltiazem T
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400145; group id 280; item number 0592; lccId None; manufacturer id JPC
Source form: SR Cap; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2133; ministry $0.2133
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02495376
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98529Interchangeable products
Diltiazem T · DIN 02516101 · $0.2133
M-Diltiazem T · DIN 02546434 · $0.2133
Mar-Diltiazem T · DIN 02465353 · $0.2133
Sandoz Diltiazem T · DIN 02245918 · $0.2133
Teva-Diltiazem HCL ER · DIN 02271605 · $0.2133
Teva-Diltiazem T · DIN 02370441 · $0.2133
Tiazac · DIN 02231150 · $0.2133
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02495376
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Diltiazem T · DIN 02546434 · 120mg · extended release capsule
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Diltiazem T · DIN 02546434
Manufacturer: Mantra Pharma Inc.; listing date 2024-10-31
Daily cost (source): $0.2133
Health Canada: Marketed since 2024-08-23 · brand M-DILTIAZEM T · ATC C08DB01 DILTIAZEM · form Capsule (extended-release) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Mantra pharma inc · schedule Prescription
M-Diltiazem T: Formulary list price $0.2133/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2133 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103512 · Verify on the e-Formulary ↗ (DIN 02546434)
Source record
DIN 02546434: M-Diltiazem T
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400145; group id 280; item number 0592; lccId None; manufacturer id MAT
Source form: SR Cap; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2133; ministry $0.2133
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02546434
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103512Interchangeable products
Diltiazem T · DIN 02516101 · $0.2133
Jamp Diltiazem T · DIN 02495376 · $0.2133
Mar-Diltiazem T · DIN 02465353 · $0.2133
Sandoz Diltiazem T · DIN 02245918 · $0.2133
Teva-Diltiazem HCL ER · DIN 02271605 · $0.2133
Teva-Diltiazem T · DIN 02370441 · $0.2133
Tiazac · DIN 02231150 · $0.2133
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02546434
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Diltiazem T · DIN 02465353 · 120mg · extended release capsule
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Diltiazem T · DIN 02465353
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2018-08-30
Daily cost (source): $0.2133
Health Canada: Marketed since 2018-05-28 · brand MAR-DILTIAZEM T · ATC C08DB01 DILTIAZEM · form Capsule (extended-release) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Diltiazem T: Formulary list price $0.2133/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2133 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95355 · Verify on the e-Formulary ↗ (DIN 02465353)
Source record
DIN 02465353: Mar-Diltiazem T
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400145; group id 280; item number 0592; lccId None; manufacturer id MAR
Source form: SR Cap; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2133; ministry $0.2133
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02465353
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95355Interchangeable products
Diltiazem T · DIN 02516101 · $0.2133
Jamp Diltiazem T · DIN 02495376 · $0.2133
M-Diltiazem T · DIN 02546434 · $0.2133
Sandoz Diltiazem T · DIN 02245918 · $0.2133
Teva-Diltiazem HCL ER · DIN 02271605 · $0.2133
Teva-Diltiazem T · DIN 02370441 · $0.2133
Tiazac · DIN 02231150 · $0.2133
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02465353
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Diltiazem T · DIN 02370441 · 120mg · extended release capsule
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Diltiazem T · DIN 02370441
Manufacturer: Teva Canada Limited; listing date 2012-01-19
Daily cost (source): $0.2133
Health Canada: Marketed since 2024-10-23 · brand TEVA-DILTIAZEM T · ATC C08DB01 DILTIAZEM · form Capsule (extended-release) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Teva canada limited · schedule Prescription
Teva-Diltiazem T: Formulary list price $0.2133/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2133 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85560 · Verify on the e-Formulary ↗ (DIN 02370441)
Source record
DIN 02370441: Teva-Diltiazem T
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400145; group id 280; item number 0592; lccId None; manufacturer id TEV
Source form: SR Cap; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2133; ministry $0.2133
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02370441
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85560Interchangeable products
Diltiazem T · DIN 02516101 · $0.2133
Jamp Diltiazem T · DIN 02495376 · $0.2133
M-Diltiazem T · DIN 02546434 · $0.2133
Mar-Diltiazem T · DIN 02465353 · $0.2133
Sandoz Diltiazem T · DIN 02245918 · $0.2133
Teva-Diltiazem HCL ER · DIN 02271605 · $0.2133
Tiazac · DIN 02231150 · $0.2133
Shortage status: discontinued (2020-05-08, reported by ACTAVIS PHARMA COMPANY); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02370441
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Tiazac · DIN 02231150 · 120mg · extended release capsule
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tiazac · DIN 02231150
Manufacturer: Valeant Canada Ltd.; listing date 1998-12-31
Daily cost (source): $1.2263
Health Canada: Marketed since 2021-06-04 · brand TIAZAC · ATC C08DB01 DILTIAZEM · form Capsule (extended-release) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Bausch health, canada inc. · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50458 · Verify on the e-Formulary ↗ (DIN 02231150)
Source record
DIN 02231150: Tiazac
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400145; group id 280; item number 0592; lccId None; manufacturer id VAL
Source form: SR Cap; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.2263; ministry $0.2133
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231150
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50458Interchangeable products
Diltiazem T · DIN 02516101 · $0.2133
Jamp Diltiazem T · DIN 02495376 · $0.2133
M-Diltiazem T · DIN 02546434 · $0.2133
Mar-Diltiazem T · DIN 02465353 · $0.2133
Sandoz Diltiazem T · DIN 02245918 · $0.2133
Teva-Diltiazem HCL ER · DIN 02271605 · $0.2133
Teva-Diltiazem T · DIN 02370441 · $0.2133
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231150
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Diltiazem XC: Formulary list price $0.9195/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9195 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91375 · Verify on the e-Formulary ↗ (DIN 02429322)
Source record
DIN 02429322: Teva-Diltiazem XC
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400162; group id 280; item number 0584; lccId None; manufacturer id TEV
Source form: ER Tab; strength: 180mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.9195; ministry $0.9195
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429322
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91375Interchangeable products
Tiazac XC · DIN 02256746 · $0.9195
Shortage status: resolved shortage (ended 2026-08-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02429322
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74196 · Verify on the e-Formulary ↗ (DIN 02256746)
Source record
DIN 02256746: Tiazac XC
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400162; group id 280; item number 0584; lccId None; manufacturer id BIO
Source form: ER Tab; strength: 180mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.4502; ministry $0.9195
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02256746
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74196Interchangeable products
Teva-Diltiazem XC · DIN 02429322 · $0.9195
Shortage status: resolved shortage (ended 2025-10-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02256746
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Diltiaz CD · DIN 02230998 · 180mg · LA capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Diltiaz CD · DIN 02230998
Manufacturer: Apotex Inc.; listing date 1997-08-28
Daily cost (source): $0.4824
Health Canada: Marketed since 1997-03-27 · brand APO-DILTIAZ CD · ATC C08DB01 DILTIAZEM · form Capsule (controlled-delivery) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 180 MG · company Apotex inc · schedule Prescription
Apo-Diltiaz CD: Formulary list price $0.4824/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4824 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50279 · Verify on the e-Formulary ↗ (DIN 02230998)
Source record
DIN 02230998: Apo-Diltiaz CD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400123; group id 280; item number 0589; lccId None; manufacturer id APX
Source form: LA Cap; strength: 180mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.4824; ministry $0.4824
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230998
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50279Interchangeable products
Cardizem CD · DIN 02097257 · $0.4824
Co Diltiazem CD · DIN 02370638 · $0.4824
Diltiazem CD · DIN 02400448 · $0.4824
Diltiazem CD · DIN 02446006 · $0.4824
Jamp Diltiazem CD · DIN 02528045 · $0.4824
M-Diltiazem CD · DIN 02546094 · $0.4824
Mar-Diltiazem CD · DIN 02484072 · $0.4824
Sandoz Diltiazem CD · DIN 02243339 · $0.4824
Teva-Diltazem CD · DIN 02242539 · $0.4824
Shortage status: active shortage (reported 2026-06-09, estimated to end 2027-01-29, last updated 2026-06-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02230998
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diltiazem CD · DIN 02400448 · 180mg · LA capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Diltiazem CD · DIN 02400448
Manufacturer: Sanis Health Inc.; listing date 2022-07-29
Daily cost (source): $0.4824
Health Canada: Marketed since 2022-04-20 · brand DILTIAZEM CD · ATC C08DB01 DILTIAZEM · form Capsule (controlled-delivery) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 180 MG · company Sanis health inc · schedule Prescription
Diltiazem CD: Formulary list price $0.4824/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4824 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88524 · Verify on the e-Formulary ↗ (DIN 02400448)
Source record
DIN 02400448: Diltiazem CD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400123; group id 280; item number 0589; lccId None; manufacturer id SAI
Source form: LA Cap; strength: 180mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.4824; ministry $0.4824
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02400448
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88524Interchangeable products
Apo-Diltiaz CD · DIN 02230998 · $0.4824
Cardizem CD · DIN 02097257 · $0.4824
Co Diltiazem CD · DIN 02370638 · $0.4824
Diltiazem CD · DIN 02446006 · $0.4824
Jamp Diltiazem CD · DIN 02528045 · $0.4824
M-Diltiazem CD · DIN 02546094 · $0.4824
Mar-Diltiazem CD · DIN 02484072 · $0.4824
Sandoz Diltiazem CD · DIN 02243339 · $0.4824
Teva-Diltazem CD · DIN 02242539 · $0.4824
Shortage status: resolved shortage (ended 2017-08-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02400448
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diltiazem CD · DIN 02446006 · 180mg · LA capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Diltiazem CD · DIN 02446006
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-07-31
Daily cost (source): $0.4824
Health Canada: Marketed since 2024-05-09 · brand DILTIAZEM CD · ATC C08DB01 DILTIAZEM · form Capsule (extended-release) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 180 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Diltiazem CD: Formulary list price $0.4824/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4824 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93127 · Verify on the e-Formulary ↗ (DIN 02446006)
Source record
DIN 02446006: Diltiazem CD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400123; group id 280; item number 0589; lccId None; manufacturer id SIV
Source form: LA Cap; strength: 180mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.4824; ministry $0.4824
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02446006
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93127Interchangeable products
Apo-Diltiaz CD · DIN 02230998 · $0.4824
Cardizem CD · DIN 02097257 · $0.4824
Co Diltiazem CD · DIN 02370638 · $0.4824
Diltiazem CD · DIN 02400448 · $0.4824
Jamp Diltiazem CD · DIN 02528045 · $0.4824
M-Diltiazem CD · DIN 02546094 · $0.4824
Mar-Diltiazem CD · DIN 02484072 · $0.4824
Sandoz Diltiazem CD · DIN 02243339 · $0.4824
Teva-Diltazem CD · DIN 02242539 · $0.4824
Shortage status: resolved shortage (ended 2024-09-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02446006
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Diltiazem CD · DIN 02528045 · 180mg · LA capsule
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Diltiazem CD · DIN 02528045
Manufacturer: Jamp Pharma Corporation; listing date 2023-01-31
Daily cost (source): $0.4824
Health Canada: Marketed since 2022-12-16 · brand JAMP DILTIAZEM CD · ATC C08DB01 DILTIAZEM · form Capsule (controlled-delivery) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 180 MG · company Jamp pharma corporation · schedule Prescription
Jamp Diltiazem CD: Formulary list price $0.4824/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4824 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101731 · Verify on the e-Formulary ↗ (DIN 02528045)
Source record
DIN 02528045: Jamp Diltiazem CD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400123; group id 280; item number 0589; lccId None; manufacturer id JPC
Source form: LA Cap; strength: 180mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.4824; ministry $0.4824
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02528045
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101731Interchangeable products
Apo-Diltiaz CD · DIN 02230998 · $0.4824
Cardizem CD · DIN 02097257 · $0.4824
Co Diltiazem CD · DIN 02370638 · $0.4824
Diltiazem CD · DIN 02400448 · $0.4824
Diltiazem CD · DIN 02446006 · $0.4824
M-Diltiazem CD · DIN 02546094 · $0.4824
Mar-Diltiazem CD · DIN 02484072 · $0.4824
Sandoz Diltiazem CD · DIN 02243339 · $0.4824
Teva-Diltazem CD · DIN 02242539 · $0.4824
Shortage status: resolved shortage (ended 2025-08-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02528045
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Diltiazem CD · DIN 02546094 · 180mg · LA capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Diltiazem CD · DIN 02546094
Manufacturer: Mantra Pharma Inc.; listing date 2024-10-31
Daily cost (source): $0.4824
Health Canada: Marketed since 2024-08-26 · brand M-DILTIAZEM CD · ATC C08DB01 DILTIAZEM · form Capsule (controlled-delivery) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 180 MG · company Mantra pharma inc · schedule Prescription
M-Diltiazem CD: Formulary list price $0.4824/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4824 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103481 · Verify on the e-Formulary ↗ (DIN 02546094)
Source record
DIN 02546094: M-Diltiazem CD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400123; group id 280; item number 0589; lccId None; manufacturer id MAT
Source form: LA Cap; strength: 180mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.4824; ministry $0.4824
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02546094
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103481Interchangeable products
Apo-Diltiaz CD · DIN 02230998 · $0.4824
Cardizem CD · DIN 02097257 · $0.4824
Co Diltiazem CD · DIN 02370638 · $0.4824
Diltiazem CD · DIN 02400448 · $0.4824
Diltiazem CD · DIN 02446006 · $0.4824
Jamp Diltiazem CD · DIN 02528045 · $0.4824
Mar-Diltiazem CD · DIN 02484072 · $0.4824
Sandoz Diltiazem CD · DIN 02243339 · $0.4824
Teva-Diltazem CD · DIN 02242539 · $0.4824
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02546094
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Diltiazem CD · DIN 02484072 · 180mg · LA capsule
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Diltiazem CD · DIN 02484072
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2020-05-29
Daily cost (source): $0.4824
Health Canada: Marketed since 2020-03-30 · brand MAR-DILTIAZEM CD · ATC C08DB01 DILTIAZEM · form Capsule (controlled-delivery) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 180 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Diltiazem CD: Formulary list price $0.4824/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4824 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97440 · Verify on the e-Formulary ↗ (DIN 02484072)
Source record
DIN 02484072: Mar-Diltiazem CD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400123; group id 280; item number 0589; lccId None; manufacturer id MAR
Source form: LA Cap; strength: 180mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.4824; ministry $0.4824
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02484072
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97440Interchangeable products
Apo-Diltiaz CD · DIN 02230998 · $0.4824
Cardizem CD · DIN 02097257 · $0.4824
Co Diltiazem CD · DIN 02370638 · $0.4824
Diltiazem CD · DIN 02400448 · $0.4824
Diltiazem CD · DIN 02446006 · $0.4824
Jamp Diltiazem CD · DIN 02528045 · $0.4824
M-Diltiazem CD · DIN 02546094 · $0.4824
Sandoz Diltiazem CD · DIN 02243339 · $0.4824
Teva-Diltazem CD · DIN 02242539 · $0.4824
Shortage status: resolved shortage (ended 2022-03-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02484072
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered
Matched class: 24:04 Cardiac Drugs
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL
Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL
24:00 CARDIOVASCULAR DRUGS
· 6 products · Listed, not a benefit (2), General benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 80mg, 120mg · Tab
· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 100mg, 200mg · Cap
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04
and 9 more
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44)
• Chronic Stable Angina
NORVASC is indicated for the management of chronic stable angina (effort-associated
angina) in patients who remain symptomatic despite adequate doses of beta-blockers
and/or organic nitrates or who cannot tolerate those agents.
PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS
AA-DILTIAZ (diltiazem hydrochloride) is indicated for:
• Angina
▪ AA-DILTIAZ (diltiazem hydrochloride) tablets may be used in the management of angina
resulting from coronary artery spasm.
▪ AA-DILTIAZ tablets are indicated for the management of chronic stable angina (effort-
associated angina) without evidence of vasospasm in patients who remain
symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who
cannot tolerate those agents. AA-DILTIAZ tablets may be tried in combination with
beta-blockers in chronic stable angina in patients with normal ventricular function.
When such concomitant therapy is introduced, patients must be monitored closely (see
7 WARNINGS AND PRECAUTIONS, Cardiovascular).
▪ AA-DILTIAZ tablets may be useful in unstable angina when spasm of the coronary
vessels is definitely a contributing factor (e.g., ST segment elevation). In the absence of
objective evidence of a spastic component, nitrates or nitrates plus a beta-blocker are
at present the treatment of choice. If, in the…
https://pdf.hres.ca/dpd_pm/00082380.PDF
PM date: DEC 31, 1988
Source product: AA-DILTIAZ; DIN 00771376; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
AA-Diltiaz · DIN 00771376
Shortage status: discontinued (2019-07-12, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00771376
Apo-Diltiaz CD · DIN 02230997
Shortage status: active shortage (reported 2026-08-25, estimated to end 2027-01-29, last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02230997
Jamp Diltiazem CD · DIN 02528037
Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-10-16, last updated 2026-07-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02528037
Teva-Diltazem CD · DIN 02242538
Shortage status: active shortage (reported 2026-06-10, estimated to end 2026-11-10, last updated 2026-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242538
Teva-Diltiazem T · DIN 02370441
Shortage status: discontinued (2020-05-08, reported by ACTAVIS PHARMA COMPANY); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02370441
Tiazac · DIN 02231150
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231150
Apo-Diltiaz CD · DIN 02230998
Shortage status: active shortage (reported 2026-06-09, estimated to end 2027-01-29, last updated 2026-06-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02230998